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Abstract
Stromal elastosis is related to good prognosis in breast cancer and fibulin-2 helps to stabilize
elastic fibers in basement membranes. Here, we examined the level of perivascular fibulin-2
expression in relation to elastosis content, vascular invasion, molecular subtypes, tumour
detection mode, and patient prognosis in breast cancer. We performed a population based
retrospective study of invasive breast cancers from the Norwegian Breast Screening Pro-
gram (Vestfold County, 2004–2009) including 200 screen-detected and 82 interval cancers.
Perivascular fibulin-2 staining was semi-quantitatively graded based on immunohistochem-
istry (1–3) and dichotomized as high expression (grade 2–3) and low expression (grade 1).
Elastosis content was graded on a 4-tiered scale and dichotomized as high (score 3) and
low (score 0–2) expression, whereas lymphatic (LVI) and blood vessel invasion (BVI) were
recorded as absent or present by immunohistochemistry. High perivascular fibulin-2 expres-
sion was strongly related to stromal elastosis (p<0.001), and inversely associated with BVI
and LVI (p<0.001 for both). High fibulin-2 was associated with luminal breast cancer sub-
groups (p<0.001) and inversely with interval cancers compared with screen-detected
tumours (p<0.001). By univariate analysis, low perivascular fibulin-2 was associated with
reduced recurrence-free survival (p = 0.002) and disease specific survival (p = 0.019).
Low perivascular fibulin-2 expression was strongly related to vascular invasion, low stromal
elastosis, non-luminal breast cancer subtypes, interval presentation, and adverse
prognosis.
Introduction
Stromal elastosis, defined as dense aggregates of elastic fibers, is found in some neoplastic tis-
sues and especially in malignant tumours of the breast [1], lung [2] and thyroid gland [3]. We
previously reported that breast cancer stromal elastosis is associated with a favorable progno-
sis, low tumour cell proliferation by Ki67 expression, and mammography detection compared
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with interval cancer presentation in a population based setting [4]. In addition, high elastosis
content correlated strongly with stellate tumour shape, low histological grade, and ER
+/HER2– status [4]. However, whether and how elastosis is mechanistically involved in
tumour development and prognosis in breast cancer is poorly understood.
Fibulins are calcium-binding glycoproteins that are linked to microfibrils in elastotic fibers,
and fibulin-2 helps to stabilize elastic fibers in basement membranes [5, 6]. Immunohisto-
chemical studies of fibulin-2 expression in normal human breast tissue have shown strong
staining, especially surrounding vessels and ducts [7]. Based on this, we hypothesized that
reduced perivascular fibulin-2 expression is associated with improved tumour cell accessibility
into breast cancer vessels and other features of aggressive tumours. Notably, the relationship
between levels of fibulin-2, vascular invasion and detection mode (screen-detected versus
interval breast cancer) has not been previously investigated. Also, to our knowledge, there is
no information on how fibulin-2 protein expression, in particular around vessel structures,
relates to prognosis in breast cancer.
The aim of this study was to establish whether perivascular fibulin-2 expression is associ-
ated with patient prognosis in breast cancer, and to see whether this expression pattern is




Patients were included from Vestfold County in Eastern Norway. Vestfold comprises 5% of
the Norwegian population with around 230,000 inhabitants. The Norwegian Breast Cancer
Screening Program involves biannual mammography in the age-group 50–69 years, and
was implemented in this county in 2004. A total of 37,977 women participated during the
study period January 2004 –December 2008, with attendance rates of 71% and 76% during
the first two screening rounds. During this period, 202 invasive screen-detected cancers and
83 invasive interval breast tumours were diagnosed after the prevalent and subsequent
rounds.
Information on completeness was received from the Cancer Registry of Norway. The
patients (age 50–69 years at diagnosis) were predominantly Caucasians living in Vestfold
County. Ten patients (7 interval cases, 3 screening cases) were excluded because only core
biopsies were available. Three other patients were also excluded due to the following reasons: 1
screen-detected cancer had no residual tumour tissue for further investigation, 1 screen-
detected tumour was diagnosed as a malignant phyllodes tumour and 1 patient with interval
cancer suffered from multiple metastases at the time of diagnosis with no biopsy or breast sur-
gery having been performed. Four patients (two screening-detected cases and two interval
cases) had cancers in both breasts, and the Nottingham Prognostic Index (NPI) was used to
select the tumour with the worst prognosis in three of them. The fourth patient showed identi-
cal NPI for both tumours, so the tumour with the highest Ki67 score was selected. Thus, a total
of 272 patients (197 screen-detected and 75 interval cases) were finally included. Clinical data
(tumour stage and survival time) were recorded from patients’ journals with last status
recorded in August 2017. The median follow-up time was 126 months (range 2–168 months).
Primary treatment of the patients included 199 resections (73%) and 73 mastectomies (27%).
In addition, 213 patients (82%) received radiation, 152 (59%) received endocrine treatment
and 70 (27%) received chemotherapy. Treatment information for 12 patients (4.4%) was
unavailable.
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Ethics statement
The study was approved by the Regional Ethics Committee of Eastern Norway (reference
#2018/1102). The Regional Ethics Committee waived the requirement for informed consent.
All histopathological and clinical data used were deidentified in this study.
Histopathological data
Tumours were classified as invasive carcinoma of no special type (NST) or special type carci-
nomas (lobular, other types). Histological grading was done according to the Nottingham cri-
teria [8]. Tumour diameter was measured microscopically in mm, and lymph node status was
included from the pathology report.
Immunohistochemistry
Whole tumour sections were used for fibulin-2 staining. Slides were placed on the Ventana
Benchmark Ultra automated immuno-stainer (Roche) and dewaxed. Heat-induced epitope
retrieval was performed with Ventana‘s Ultra CC1 retrieval solution for 56 minutes at 99˚C
followed by incubation with a rabbit polyclonal anti-fibulin-2 antibody (Thermo Fisher, prod-
uct number PA5-51665 and lot number A35146) at a 1:200 dilution in Ventana Antibody Dil-
uent (251–018) for 32 minutes at 36˚C. Presence of the antigen was visualized by using the
OptiView DAB detection kit (Roche).
Evaluation of staining. Fibulin-2 staining was detected around vessels (perivascular
stroma), especially related to small vessels localized in the tumour periphery, close to the inva-
sive border. Perivascular fibulin-2 staining was evaluated on the basis of the predominant
staining pattern, and staining intensities in the tumour were graded in a semiquantitative
manner from 1 to 3. Tumours were assigned staining grade 1 if fibulin-2 staining was absent
or faint/barely perceptible in >50% of tumour vessels; grade 2, if weak to moderate peripheral
staining was seen in>50% of tumour vessels; and grade 3, if stronger and thicker circumferen-
tial perivascular staining was observed in > 50% of tumour vessels (Fig 1).
For statistical analysis, perivascular fibulin-2 level was dichotomized as low-grade expres-
sion (staining grade 1) and high-grade expression (staining grade 2–3). To estimate inter-
observer agreement for this grading system, 50 cases were examined by two pathologists (T.A.
K., Y.C.) showing good agreement with kappa value of 0.70. Disagreement was only related to
cases graded 2 or 3.
Some data from previous studies were included in this cohort for association analysis and
comparisons. Briefly, the amount of elastosis was evaluated and graded by microscopy of stan-
dard sections in a semiquantitative manner from 0–3 according to Shivas and Douglas [9]. For
statistical analysis, cases were divided into two categories: low elastosis (grade 0–2) with no or
limited elastosis, and high elastosis content (grade 3) with extensive elastosis. Immunohis-
tochemistry and evaluation of lymph vessel invasion (LVI) and blood vessel invasion (BVI) by
D2-40 staining and CD31 staining, respectively, have previously been reported by us [10, 11],
using whole sections. We recorded LVI to be present if tumour tissue was located within more
than one D2-40 positive structure with weak or negative CD31 staining. On the other hand,
BVI was reported when tumour emboli were detected in one or more CD31 positive and D2-
40 negative vessels [10, 11]. Surrogate markers for molecular subtypes of breast cancer were
defined and applied according to the St Gallen 2013 consensus [12]. The cut-off point for
estrogen and progesterone receptors was 1% in the present study. Positivity for CK5/6 and/or
P-cadherin was used to define basal-like differentiation [13, 14]. For Ki67 evaluation, 500
tumour cell nuclei were counted (hotspots) and the Ki67 positive fraction (%) was calculated.
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Fig 1. Histological images of perivascular fibulin-2 expression by immuno-histochemistry. Histological images of
tumour tissue with absent or faint/barely perceptible peripheral staining in tumour vessels (A), weak to moderate
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Statistical methods
Statistical analyses were performed using IBM SPSS Statistics, version 25.0 (Armonk, NY: IBM
Corp.). Two-sided p-values of<0.05 were considered statistically significant. Associations
between categorical variables were assessed by Pearson’s chi-square (χ2) test. In univariate
Kaplan-Meier survival analyses (log-rank test for differences), disease recurrence and death
from breast cancer were end-points (recurrence free and disease specific survival, RFS and
DSS). Entry date was the time of diagnosis. Patients who died from other causes were censored
at the date of death. The Cox´ proportional hazards method was used for multivariate survival
analyses. Death from breast cancer was used as end-point. Variables were visually examined by
log-minus-log plots to check proportionality assumptions. A multivariate analysis was con-
ducted for perivascular fibulin-2 content together with standard prognostic variables. For statis-
tical analysis, perivascular fibulin-2 amount was dichotomized as low-grade expression
(staining grade 1) and high-grade expression (staining grade 2–3). After exclusion of a few cases
(see above), a total of 272 patients were available for survival analyses in the current study.
Results
Staining patterns and distribution of fibulin-2
Fibulin-2 was predominantly expressed in the perivascular region. However, weak to strong
fibulin-2 staining was also observed in the periphery of ductal carcinoma in situ (periductal
staining), and in a few normal vessels and benign ducts in the tumour surroundings.
High perivascular fibulin-2 expression associates with clinico-pathological
characteristics of good prognosis
In our series, 201 cases (74%) showed high-grade perivascular fibulin-2 expression, whereas 71
cases (26%) showed low-grade staining. Table 1 presents the basic clinico-pathological features
in relation to amount of fibulin-2 around vessels in the study population. High perivascular
fibulin-2 was related to predictors of good prognosis including low histological grade, ER and
PR positivity, negative HER2 status and high Ki67 index (upper quartile; all p<0.001). Trends
were also present for associations between perivascular fibulin-2 expression and small tumour
size (< 2 cm) (p = 0.056), as well as negative nodal status (p = 0.068).
High perivascular fibulin-2 expression is related to tumour stromal
elastosis and associates inversely with vessel invasion in breast cancer
Among the 272 cases in this study, 45 (17%) had high elastosis content, whereas 227 (83%) had
low elastosis. We found a strong and significant relation between high stromal elastosis and
high perivascular fibulin-2 expression (p<0.001; Table 2). Evaluation of vessel invasion
revealed tumours that had either LVI (n = 45, 16%) or BVI (n = 18, 6%) or both LVI and BVI
(n = 25, 9%), giving overall frequencies of 25% and 15% for LVI and BVI, respectively. High
perivascular fibulin-2 was inversely associated with BVI and LVI (both p<0.001) as compared
to tumours without BVI or LVI (Table 2).
staining (B), or strong/thick staining (C) for fibulin-2 in vessels at the tumour periphery (x200). Scale bars are shown
on each image.
https://doi.org/10.1371/journal.pone.0249767.g001
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High perivascular fibulin-2 expression is associated with luminal breast
cancer subgroups and inversely associated with basal-like phenotype and
interval breast cancer
The cohort used in our study showed 53% Luminal A, 31% Luminal B (HER2-negative), 5%
Luminal B (HER2-positive), 3% HER2-type, and 8%Triple-negative tumours. Perivascular
fibulin-2 staining was significantly associated with molecular subtypes (P<0.001) (Table 3)
according to the St Gallen 2013 consensus.
HER2-positive and Triple-negative tumours demonstrated typically low perivascular fibu-
lin-2 compared to Luminal A and Luminal B (HER2-negative tumours). Furthermore, cases
with high perivascular fibulin-2 were inversely associated with basal-like tumours and interval
cancers (both p< 0.001; Table 2).
Survival analyses
The median follow-up period for survivors was 126 months (range 2–168 months). Among
272 patients, distant metastases or local tumour recurrence was observed at follow-up in 42
patients, 32 patients died of breast cancer.
Table 1. Associations between perivascular fibulin-2 expression and clinico-pathological features (n = 272).
Variable Perivascular fibulin-2
High Low
Histologic type N N (%) N (%) OR P-value
Others 52 47 (90) 5 (10) 1 0.003
Carcinoma NST 220 154 (70) 66 (30) 4.0 (1.5–10.6)
Tumour diameter
< 2cm 210 161 (77) 49 (13) 1 0.056
� 2cm 62 40 (65) 22 (35) 1.8 (0.98–3.3)
Histologic grade
1 75 72 (96) 3 (4) 1 <0.001
2–3 197 129 (65) 68 (35) 12.3 (3.8–41.7)
Lymph node status
Negative 181 140 (77) 41 (23) 1 0.068
Positive 91 61 (67) 30 (33) 1.7 (0.9–3.0)
ER
Positive 239 191 (80) 48 (20) 1 <0.001
Negative 33 10 (30) 23 (70) 9.2 (4.1–20.5)
PR
Positive 181 147 (81) 34 (19) 1 <0.001
Negative 91 54 (59) 37 (41) 2.9 (1,7–5.2)
HER 2 status
Negative 249 195 (78) 54 (22) 1 <0.001
Positive 23 6 (26) 17 (74) 10.2 (3.8–27.2)
Ki67
Low 209 172 (82) 37 (18) 1 <0.001
High 63 29 (46) 34 (54) 5.5 (3.0–10.0)
P-values were obtained using Pearson´s Chi square test. Perivascular fibulin-2 was graded on immunohistochemical slides.
https://doi.org/10.1371/journal.pone.0249767.t001
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Univariate analysis revealed that low perivascular fibulin-2 (score 1) was associated with
reduced recurrence-free survival (RFS) and disease specific survival (DSS), compared to high
perivascular fibulin-2 (score 2–3; Fig 2).
Notably, perivascular fibulin-2 did not associate significantly with survival within the five
St. Gallen subtypes when analyzed individually. To note, each subgroup had few cases and
events. However, when Luminal A and Luminal B (HER2-negative) tumours were combined
in one group and analyzed, low perivascular fibulin-2 was associated with reduced RFS
(p = 0.001), but not DSS (p = 0.14).
Univariate analysis of vessel invasion with respect to RFS and DFS revealed that BVI and
LVI were significantly associated with reduced RFS and DSS (all p�0.005; S1 Fig).
We then divided the whole patient series into three groups based on BVI or LVI status (pos-
itive/negative) in combination with fibulin-2 expression levels (high/low), and performed uni-
variate analysis on groups with: (1) BVI + or LVI+ and low perivascular fibulin-2, (2) BVI- or
LVI- and high perivascular fibulin-2 and (3) all other cases (BVI and/or LVI positive with high
perivascular fibulin-2 or BVI and/or LVI negative with low perivascular fibulin-2).




N N (%) N (%) OR P-value
Elastosis High 45 2 (3) 43 (96) 1 <0.001
Low 227 69 (30) 158 (70) 9.4 (2.2–39.9)
BVI Negative 233 48 (21) 185 (79) 1 <0.001
Positive 39 23 (59) 16 (41) 5.5 (2.7–11.3)
LVI Negative 207 40 (19) 167 (81) 1 <0.001
Positive 65 31 (48) 34 (52) 3.8 (2.1–6.9)
Basal-like No 224 46 (21) 178 (79) 1 <0.001
Yes 48 25 (52) 23 (48) 4.2 (2.2–8.1)
Triple negative No 251 57 (23) 194 (77) 1 <0.001
Yes 21 14 (67) 7 (33) 6.8 (2.6–17.7)
Detection mode Screening 197 38 (19) 159 (81) 1 <0.001
Interval 75 33 (44) 42 (56) 3.3 (1.8–5.9)
P-values were obtained using Pearson´s Chi square test. Perivascular fibulin-2 expression was graded on immunohistochemical slides.
Abbreviations: BVI, blood vessel invasion; LVI, lymph vessel invasion; N, number of cases; OR, odds ratio.
https://doi.org/10.1371/journal.pone.0249767.t002
Table 3. Association between perivascular fibulin-2 expression and tumour subtypes (n = 272).
Luminal A Luminal B HER2- Luminal B HER2+ HER2 type Triple negative Total
N (%) N (%) N (%) N (%) N (%) P-value N
Total 144 (53) 84 (31) 14 (5) 9 (3) 21 (8) 272
Perivascular fibulin-2
Low 18 (13) 22 (26) 10 (71) 7 (78) 14 (67) <0.001 71
High 126 (87) 62 (74) 4 (29) 2 (22) 7 (33) 201
Number of cases (N) and % within molecular subgroups is given according to the St Gallen 2013 consensus. P-values were obtained using Pearson‘s Chi square test.
Perivascular fibulin-2 expression was graded on immunohistochemical slides.
https://doi.org/10.1371/journal.pone.0249767.t003
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Significant differences for RFS and DSS were found for both BVI (Fig 3A and 3B) and LVI
(Fig 3C and 3D)-based groups.
Multivariate analysis of RFS was performed for all cases by including perivascular fibulin-2
expression along with basic histopathologic markers such as tumour diameter, histologic
grade and lymph node status. Here, fibulin-2 expression showed a borderline significant asso-
ciation with RFS (p = 0.052; Table 4).
When including age (as a continuous variable) in addition to fibulin-2 expression along
with tumour diameter, histologic grade and lymph node status in an alternative multivariate
model, fibulin-2 was significant (HR = 1.88; 95% CI 1.00–3.54; p = 0.050) in addition to lymph
node status (HR = 3.27; 95% CI 1.71–6.27; p<0.0005), whereas tumour diameter (p = 0.56),
histologic grade (p = 0.09) and age (p = 0.10) were not significant in this series.
For comparison and validation of the cohort, a multivariate analysis of standard prognostic
variables alone showed independent impact for histologic grade (p = 0.026) and lymph node
status (p< 0.001), but not for tumour diameter in this population- based cohort (S1 Table).
Fig 2. Estimated recurrence free and disease specific survival according to high-grade or low-grade perivascular fibulin-2 expression. Survival
curves were estimated by the Kaplan-Meier method (with log-rank test for differences). For each category, number of events / total number of cases
are given.
https://doi.org/10.1371/journal.pone.0249767.g002
Fig 3. Estimated recurrence free and disease specific survival according to high-grade or low-grade perivascular fibulin-2 expression in combinations with BVI or
LVI positive or negative cases. Survival curves are estimated by the Kaplan-Meier method (with log-rank test for differences). For each category, number of events /
total number of cases are given. The category ‘other cases’ is defined as BVI positive with high perivascular fibulin-2 or BVI negative with low perivascular fibulin-2.
https://doi.org/10.1371/journal.pone.0249767.g003
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Multivariate analysis was also done for the same basic histopathologic factors in addition to
perivascular fibulin-2 expression within the group of luminal (HER-2 negative) tumours. Low
perivascular fibulin-2 in this subgroup showed a weaker association with shorter RFS
(p = 0.12; (S2 Table) compared with low perivascular fibulin-2 in the whole series.
Discussion
Previous studies have shown that fibulin-2 exhibits a high affinity for elastin [15]. The present
study indicates a strong association between fibulin-2 expression and high amount of elastotic
stroma in breast tumours. Since elastosis is a positive prognostic factor in breast cancer, our
data are in line with findings that fibulin-2 expression reduces cell motility as well as invasion
capacities in breast cancer cell lines [16]. Hypothetically, low elastosis content, and therefore a
low fibulin-2 content, may facilitate tumour cell migration and invasion. Furthermore, fibulin-
2 binds several proteins including fibronectin, laminin and nidogen, which act as scaffolds in
basement membranes [17]. To speculate, a reduced anchoring of fibulin-2 could destabilize
basement membranes and enhance the ability of tumour cells to migrate and invade through
the ECM.
Although other fibulins might also interact with elastic fibers [18–20], we decided to use
fibulin-2 in this study because of the perivascular staining pattern observed in normal breast
tissue [7]. As a novel observation, we found a strong association between low (reduced) peri-
vascular fibulin-2 content and both blood vascular invasion (BVI) and lymphatic involvement
(LVI). Low fibulin-2 expression may possibly enhance metalloproteinase (MMP) activity, and
thereby contribute to vessel invasion as seen in our study. In line with this, Fontanil et al. dem-
onstrated that fibulin-2 might exert its tumour suppressor function by interaction with
ADAMTS-12, a secreted MMP, while ADAMTS-12 may elicit pro-tumour effects in the
absence of fibulin-2 [21]. MMPs induce proteolytic degradation of basement membranes and
promote breast carcinoma intravasation in leaky vessels [22].
In contrast to a suppressive role in breast cancer, experimental studies from other organs
have suggested that fibulin-2 may contribute to metastases and invasion in lung and pancreatic
adenocarcinoma cell lines [23, 24], suggesting organ specific properties of fibulin-2. Because of
this context dependence, fibulin-2 may also be of importance to metastases in breast cancer
and might potentially have a different role. Fibulin-2 promotes cross-linking of collagen and
migration of tumour cells in primary lung adenocarcinoma [23], and it would be of interest to
explore its role in the metastatic setting. Interestingly, reduced levels of fibulin-5 in breast
Table 4. Univariate and multivariate recurrence free survival analysis (Cox‘proportional hazard method) of pathological variables and perivascular fibulin-2 by
immunohistochemistry (n = 272).
Variables Categories Univariate analysis Multivariate analysis
HR (95%CI) p-value HR (95% CI) p-value
Perivascular fibulin-2 High 1 1
Low 2.5 (1.4–4.6) 0.003 1.9 (0.99–3.5) 0.052
Tumour diameter < 2cm 1 1
�2cm 2.5 (1.3–4.5) 0.003 1.3 (0.7–2.5) 0.431
Histologic grade 1 1 1
2–3 4.0 (1.4–11.2) 0.008 2.5 (0.9–7.6) 0.092
Lymph node status Negative 1 1
Positive 4.0 (2.1–7.3) <0.001 3.2 (1.7–7.6) <0.001
Abbreviations: HR, hazard ratio; 95% CI; 95% confidence interval.
https://doi.org/10.1371/journal.pone.0249767.t004
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cancer have been reported to be required for metastasis formation in the liver and lung by sup-
pressing the activity of MMP9, a protease that remodels the ECM during metastatic niche for-
mation and promotes metastatic outgrowth [20].
It has been shown that differences in prognostic factors such as tumour diameter, histologic
grade and lymph node status do not fully predict the difference between screen-detected and
interval breast cancers [25, 26]. This is consistent with the observations that detection mode is
an independent prognostic factor [27, 28]. We have previously reported a strong association
between BVI and interval breast cancer [11]. The present study indicates a link between low
perivascular fibulin-2 expression and interval breast cancer. Interval-detected tumours are
more often basal-like and HER2-positive [27, 29], and demonstrate a stiffer collagen stroma
compared to screen-detected tumours [30]. Importantly, expression of matrix remodeling
genes such as MMPs and collagen cross-linkers is predictive of a poor prognosis for breast can-
cer patients [31]. To speculate, interval breast cancers with low perivascular fibulin-2 content
may have more collagen cross-linking and collagen linearization. This may help tumour cells
to migrate into vascular channels, as an early step of metastatic spread.
In conclusion, this population-based study indicates a strong relation between reduced
perivascular fibulin-2 content and vascular invasion as well as tumour detection during screen-
ing intervals. Furthermore, low elastosis content and low fibulin-2 expression are strongly
related. The presence of low perivascular fibulin-2 was more often observed in non-luminal
subgroups and basal-like breast cancer and was associated with adverse prognosis.
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